These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
387 related articles for article (PubMed ID: 26189058)
1. Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination. Ken S; Deviers A; Filleron T; Catalaa I; Lotterie JA; Khalifa J; Lubrano V; Berry I; Péran P; Celsis P; Moyal EC; Laprie A J Neurooncol; 2015 Sep; 124(3):465-73. PubMed ID: 26189058 [TBL] [Abstract][Full Text] [Related]
2. Dynamic susceptibility contrast-enhanced perfusion magnetic resonance (MR) imaging combined with contrast-enhanced MR imaging in the follow-up of immunogene-treated glioblastoma multiforme. Stenberg L; Englund E; Wirestam R; Siesjö P; Salford LG; Larsson EM Acta Radiol; 2006 Oct; 47(8):852-61. PubMed ID: 17050367 [TBL] [Abstract][Full Text] [Related]
3. Use of dynamic susceptibility-contrast MRI (DSC-MRI) to assess perfusion changes in the ipsilateral brain parenchyma from glioblastoma. Ulmer S; Liess C; Kesari S; Otto N; Straube T; Jansen O J Neurooncol; 2009 Jan; 91(2):213-20. PubMed ID: 18807224 [TBL] [Abstract][Full Text] [Related]
4. Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI. Romano A; Pasquini L; Di Napoli A; Tavanti F; Boellis A; Rossi Espagnet MC; Minniti G; Bozzao A J Neurooncol; 2018 Sep; 139(2):455-460. PubMed ID: 29721752 [TBL] [Abstract][Full Text] [Related]
5. Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab. Leu K; Boxerman JL; Lai A; Nghiemphu PL; Pope WB; Cloughesy TF; Ellingson BM J Magn Reson Imaging; 2016 Nov; 44(5):1229-1237. PubMed ID: 26971534 [TBL] [Abstract][Full Text] [Related]
6. Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas. Thomsen H; Steffensen E; Larsson EM Acta Radiol; 2012 Feb; 53(1):95-101. PubMed ID: 22114021 [TBL] [Abstract][Full Text] [Related]
7. Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation? Khalifa J; Tensaouti F; Lotterie JA; Catalaa I; Chaltiel L; Benouaich-Amiel A; Gomez-Roca C; Noël G; Truc G; Péran P; Berry I; Sunyach MP; Charissoux M; Johnson C; Cohen-Jonathan Moyal E; Laprie A J Neurooncol; 2016 Oct; 130(1):181-192. PubMed ID: 27502603 [TBL] [Abstract][Full Text] [Related]
8. Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters. Bag AK; Cezayirli PC; Davenport JJ; Gaddikeri S; Fathallah-Shaykh HM; Cantor A; Han XS; Nabors LB J Neurooncol; 2014 Nov; 120(2):361-70. PubMed ID: 25098699 [TBL] [Abstract][Full Text] [Related]
9. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027 [TBL] [Abstract][Full Text] [Related]
10. Prognostic value of relative cerebral blood volume in patients with recurrent glioblastoma multiforme treated with bevacizumab. Stecco A; Amatuzzo P; Sponghini AP; Platini F; Quagliozzi M; Buemi F; Guenzi E; Carriero A J Neurosurg Sci; 2019 Aug; 63(4):394-401. PubMed ID: 27603407 [TBL] [Abstract][Full Text] [Related]
11. Diagnostic accuracy of automatic normalization of CBV in glioma grading using T1- weighted DCE-MRI. Sahoo P; Gupta RK; Gupta PK; Awasthi A; Pandey CM; Gupta M; Patir R; Vaishya S; Ahlawat S; Saha I Magn Reson Imaging; 2017 Dec; 44():32-37. PubMed ID: 28827098 [TBL] [Abstract][Full Text] [Related]
12. Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms. Provenzale JM; York G; Moya MG; Parks L; Choma M; Kealey S; Cole P; Serajuddin H AJR Am J Roentgenol; 2006 Oct; 187(4):1036-42. PubMed ID: 16985154 [TBL] [Abstract][Full Text] [Related]
13. Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. Mangla R; Singh G; Ziegelitz D; Milano MT; Korones DN; Zhong J; Ekholm SE Radiology; 2010 Aug; 256(2):575-84. PubMed ID: 20529987 [TBL] [Abstract][Full Text] [Related]
14. Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: Comparison of intraindividually matched T1 - and T2 (*) -based bolus techniques. Bonekamp D; Deike K; Wiestler B; Wick W; Bendszus M; Radbruch A; Heiland S J Magn Reson Imaging; 2015 Jul; 42(1):87-96. PubMed ID: 25244574 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme. Deviers A; Ken S; Filleron T; Rowland B; Laruelo A; Catalaa I; Lubrano V; Celsis P; Berry I; Mogicato G; Cohen-Jonathan Moyal E; Laprie A Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):385-93. PubMed ID: 25104068 [TBL] [Abstract][Full Text] [Related]
16. Impact of Software Modeling on the Accuracy of Perfusion MRI in Glioma. Hu LS; Kelm Z; Korfiatis P; Dueck AC; Elrod C; Ellingson BM; Kaufmann TJ; Eschbacher JM; Karis JP; Smith K; Nakaji P; Brinkman D; Pafundi D; Baxter LC; Erickson BJ AJNR Am J Neuroradiol; 2015 Dec; 36(12):2242-9. PubMed ID: 26359151 [TBL] [Abstract][Full Text] [Related]
17. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma. Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741 [TBL] [Abstract][Full Text] [Related]
18. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089 [TBL] [Abstract][Full Text] [Related]
19. Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Law M; Oh S; Johnson G; Babb JS; Zagzag D; Golfinos J; Kelly PJ Neurosurgery; 2006 Jun; 58(6):1099-107; discussion 1099-107. PubMed ID: 16723889 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. Saraswathy S; Crawford FW; Lamborn KR; Pirzkall A; Chang S; Cha S; Nelson SJ J Neurooncol; 2009 Jan; 91(1):69-81. PubMed ID: 18810326 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]